Page 34 - COVID-19-Mortality-review-in-Malaysia-and-updates-on-clinical-management-of-COVID-19

Remdesivir for Treatment of COVID-19: Mortality

Results

They did not have complete data for mortality because it was published very early. The
overall mortality benefit was 0.70 or 30% of the better mortality rate, but it was not a

significant difference [7]. Overall, there was no mortality benefit. The study was either
not powered enough for that or the study was terminated too early. The best signal
was for category 5, in patients who require oxygen. In category 6 and category 7 where

the patients required ventilation and or acquired high-flow masks and non-invasive
ventilation, it did not seem to make a difference. Maybe the antiviral alone is not
enough in these groups. Maybe what the UK recovery study did was the anti-

inflammatory drugs were required in these particular groups. The antivirals made a
difference in these groups as far as mortality benefit is concerned. But none of the

data were statistically significant. We are waiting for more data from this particular
study.

Diagram 16: Mortality data from the Remdesivir for the treatment of COVID-19
study by Beigel et al.